Veradermics (MANE) Non-Current Assets (2025 - 2026)
Veradermics posted quarterly Non-Current Assets of $287000.0 for Q1 2026, up 129.6% on a QoQ basis from $125000.0 in Q4 2025.
Veradermics (MANE) has 2 years of Non-Current Assets data on file, last reported at $287000.0 in Q1 2026.
- For the quarter ending Q1 2026, Non-Current Assets changed N/A year-over-year to $287000.0; the trailing twelve-month figure through Mar 2026 stood at $287000.0 (changed N/A YoY), and the FY2025 full-year result was $125000.0, changed N/A from the prior year.
- Non-Current Assets for Q1 2026 stood at $287000.0, up from $125000.0 in the prior quarter.
- Across five years, Non-Current Assets topped out at $287000.0 in Q1 2026 and bottomed at $125000.0 in Q4 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 4.56 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | 62,953.78 |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 486.60 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | 5.83 Mn |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 30.30 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 14.75 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 22.66 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 910.24 Mn |
| 10 | Veradermics | 2.29 Bn | 2.29 Bn | - | 287,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 287,000.00 |
| Dec 31, 2025 | 125,000.00 |